The novel method presented elicits a human IgG response to tumor antigens in vitro. Pancreas cancer cell (PANC-1) antigens can induce such anti-tumor antibodies. This response has the potential to generate antibodies specific to PANC-1 antigens. Pancreas cell line BxPC3 suppresses such an IgG response. This study underlines the importance of personalized tumor approaches.